Extending the benefit of PARP inhibitors through combinations for advanced prostate cancer - Conversation 3

touchMDT for touchONCOLOGY Listen to a medical oncologist, a urologist and an oncology pharmacist discuss extending the benefit of PARP inhibitors through combinations for the treatment of advanced prostate cancer.  The multidisciplinary team  Medical Oncologist: Dr Wassim Abida, USA Urologist: Professor Axel Merseburger, Germany Oncology Pharmacist: Dr Lisa Holle, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitor-combinations-in-advanced-prostate-cancer/